discuss the future of the bone graft substitutes and the uniqueness of iFACTOR Peptide Enhanced Bone Graft, a small peptide technology in an interview with Kim French, Sr.

This unique drug-device technology enhances the body's natural bone healing process through cellular activity that is directional and predictable. Cerapedics’ CEO Glen Kashuba and President and COO Jeff Marx, Ph.D. i-FACTOR Peptide Enhanced Bone Graft is the. “We are fortunate to be supported by KCK Group, a partner that shares in the long-term vision that differentiated products that provide safety, efficacy and economic value, supported by human clinical results, will ultimately provide the highest value to surgeons and their patients.'Īccording to the company, i-FACTOR Peptide Enhanced Bone Graft is based on proprietary biomimetic small peptide (P-15) technology that has a novel mechanism of action (attract, attach, and activate) that induces osteoblast cell proliferation and differentiation to accelerate new bone formation in patients with degenerative disc disease. Cerapedics is an orthobiologics company focused on developing and commercializing its proprietary synthetic small peptide (P-15) technology platform. We also understand the value of Level I human clinical data and are committed to investing and expanding our indications.” bone grafts that enhance and accelerate bone growth in a variety of orthopaedic procedures. 'This year we have exceeded our own expectations regarding year-over-year revenue growth and have significantly expanded our user base as surgeons continue to express a high level of satisfaction with clinical results that support the safety and efficacy of our product. Kashuba, chief executive officer of Cerapedics. 'We are pleased to announce that we have successfully completed an equity financing that will continue to accelerate the commercial release of i-FACTOR Peptide Enhanced Bone Graft and support the execution of a second Level I investigational device exemption (IDE) human clinical study that will broaden our market indication in the $2 billion U.S. ABM/P-15 has been in human clinical use for more than 17 years in an estimated 500,000 patients worldwide. Cerapedics, based in Westminster, Colorado, has announced that the company has completed a $22 million financing led by KCK Group, a family investment fund. i-FACTOR Biologic Bone Graft novel mechanism of action enhances the body’s natural bone healing process, resulting in safe, predictable bone formation. Background: i-Factor Bone Graft (Cerapedics Inc, Westminster, Colorado) is a composite bone substitute material consisting of P-15 synthetic collagen fragment adsorbed onto anorganic bone mineral suspended in an inert biocompatible hydrogel carrier.

Ifactor cerapedics